23 August 2026
: Case report
Voriconazole-Induced Pancreatitis Despite Therapeutic Trough Concentrations During Treatment of Disseminated Fusariosis in a Hospitalized Patient
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction, Rare disease
Brunelda Aristilde ABDE 1, Marta E. Berguido de la GuardiaDOI: 10.12659/AJCR.953733
Am J Case Rep 2026; 27:e953733
Abstract
BACKGROUND: Invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients, particularly those with hematologic malignancies. Disseminated fusariosis is a severe fungal infection associated with high mortality and often requires prolonged antifungal therapy. Voriconazole, a triazole antifungal with activity against Fusarium species, is commonly used but is associated with variable pharmacokinetics and potential toxicities. Acute pancreatitis despite therapeutic drug level is a rare adverse effect of voriconazole.
CASE REPORT: We present the case of a 62-year-old man with relapsed myelodysplastic syndrome progressing to acute myeloid leukemia who developed disseminated Fusarium infection confirmed by skin biopsy and culture. He was initially treated with amphotericin B and isavuconazonium, then transitioned to voriconazole for targeted antifungal therapy. After 18 days of therapy, he developed acute epigastric pain and poor oral intake. Evaluation demonstrated acute pancreatitis based on characteristic abdominal pain, elevated serum lipase, and imaging findings consistent with acute interstitial edematous pancreatitis. Alternative etiologies were excluded, including gallstones, alcohol use, hypercalcemia, and severe hypertriglyceridemia. Voriconazole was discontinued due to concern for drug-induced pancreatitis despite therapeutic trough levels between 1 and 2.1 mcg/mL, and antifungal therapy was transitioned back to isavuconazonium while continuing amphotericin B. Symptoms improved within 24 hours and resolved completely within 48 hours following drug discontinuation, supporting a probable diagnosis of voriconazole-induced pancreatitis.
CONCLUSIONS: This case highlights voriconazole-induced pancreatitis as a clinically important adverse event that may occur despite therapeutic drug levels. Early recognition and prompt drug discontinuation can lead to rapid clinical recovery and allow for transition to alternative antifungal therapy.
Keywords: Antifungal Agents, pancreatitis, voriconazole
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952819
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952834
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953320
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952980
Most Viewed Current Articles
07 Dec 2021 : Case report
22,766,348
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
177,710
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
121,485
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
66,591
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






